Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 10/20 | 0.39 |
| ▸ | BCHE | P06276 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26290154 | 0.81 | ABCB1 (0.46) | ABCB1BCHE | |
| SCHEMBL20227072 | 0.79 | ALDH1A1 (0.40) | ABCB1BCHEALDH1A1 | |
| SCHEMBL25398613 | 0.78 | MAPT (0.41) | ABCB1MAPK1HIF1AALDH1A1 | |
| SCHEMBL17359828 | 0.76 | ABCB1 (0.40) | ABCB1 | |
| SCHEMBL5492148 | 0.75 | MAPT (0.48) | ABCB1BCHE | |
| SCHEMBL11398254 | 0.75 | ABCB1 (0.43) | ABCB1BCHE | |
| SCHEMBL7152559 | 0.75 | ABCB1 (0.43) | ABCB1BCHEALDH1A1 | |
| SCHEMBL7149873 | 0.75 | ABCB1 (0.43) | ABCB1BCHE | |
| SCHEMBL5492143 | 0.75 | MAPT (0.48) | ABCB1BCHE | |
| SCHEMBL5487793 | 0.74 | ABCB1 (0.44) | ABCB1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | ABCB1 1117/4885BCHE 1486/4885MAPK1 150/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | ABCB1 1117/4885BCHE 1486/4885MAPK1 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.